CDKN1B and melanoma: In this paper, we could also show that, in BLM melanoma cells, ERβ agonists exert their antiproliferative activity through the modulation of cell cycle progressing factors (cyclin D1, cyclin D3, p27), without triggering the apoptosis pathway.